| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer E Van Cutsem, M Peeters, S Siena, Y Humblet, A Hendlisz, B Neyns, ... Journal of clinical oncology 25 (13), 1658-1664, 2007 | 2409 | 2007 |
| Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial AX Zhu, RS Finn, J Edeline, S Cattan, S Ogasawara, D Palmer, ... The Lancet Oncology 19 (7), 940-952, 2018 | 2097 | 2018 |
| Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Ducreux, AS Cuhna, C Caramella, A Hollebecque, P Burtin, D Goéré, ... Annals of oncology 26, v56-v68, 2015 | 1489 | 2015 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1130 | 2018 |
| KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab W De Roock, H Piessevaux, J De Schutter, M Janssens, G De Hertogh, ... Annals of Oncology 19 (3), 508-515, 2008 | 1095 | 2008 |
| Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib … P Hammel, F Huguet, JL van Laethem, D Goldstein, B Glimelius, P Artru, ... Jama 315 (17), 1844-1853, 2016 | 1019 | 2016 |
| Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study JF Bosset, G Calais, L Mineur, P Maingon, S Stojanovic-Rundic, ... The lancet oncology 15 (2), 184-190, 2014 | 802 | 2014 |
| Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer E Van Cutsem, WL Vervenne, J Bennouna, Y Humblet, S Gill, ... Journal of clinical oncology 27 (13), 2231-2237, 2009 | 791 | 2009 |
| Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status … T André, A De Gramont, D Vernerey, B Chibaudel, F Bonnetain, ... Journal of clinical oncology: official journal of the American Society of …, 2015 | 697 | 2015 |
| nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial D Goldstein, RH El-Maraghi, P Hammel, V Heinemann, V Kunzmann, ... Journal of the National Cancer Institute 107 (2), dju413, 2015 | 687 | 2015 |
| Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study A Santoro, L Rimassa, I Borbath, B Daniele, S Salvagni, JL Van Laethem, ... The lancet oncology 14 (1), 55-63, 2013 | 655 | 2013 |
| Addressing the challenges of pancreatic cancer: future directions for improving outcomes M Hidalgo, S Cascinu, J Kleeff, R Labianca, JM Löhr, J Neoptolemos, ... Pancreatology 15 (1), 8-18, 2015 | 590 | 2015 |
| Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal … A Hendlisz, M Van den Eynde, M Peeters, G Maleux, B Lambert, ... J Clin Oncol 28 (23), 3687-3694, 2010 | 492 | 2010 |
| Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features F Puleo, R Nicolle, Y Blum, J Cros, L Marisa, P Demetter, E Quertinmont, ... Gastroenterology 155 (6), 1999-2013. e3, 2018 | 423 | 2018 |
| Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer J Tabernero, E Van Cutsem, E Díaz-Rubio, A Cervantes, Y Humblet, ... Journal of clinical oncology 25 (33), 5225-5232, 2007 | 402 | 2007 |
| Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab B Jacobs, W De Roock, H Piessevaux, R Van Oirbeek, B Biesmans, ... Journal of clinical oncology 27 (30), 5068-5074, 2009 | 401 | 2009 |
| A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer H Oettle, D Richards, RK Ramanathan, JL Van Laethem, M Peeters, ... Annals of Oncology 16 (10), 1639-1645, 2005 | 399 | 2005 |
| Endoscopic ultrasound elastography for evaluation of lymph nodes and pancreatic masses: a multicenter study M Giovannini, T Botelberge, E Bories, C Pesenti, F Caillol, B Esterni, ... World journal of gastroenterology: WJG 15 (13), 1587, 2009 | 398 | 2009 |
| Interleukin‐10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice H Louis, JL Van Laethem, W Wu, E Quertinmont, C Degraef, ... Hepatology 28 (6), 1607-1615, 1998 | 358 | 1998 |
| Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus JL Van Laethem, MO Peny, I Salmon, M Cremer, J Devière Gut 46 (4), 574-577, 2000 | 327 | 2000 |
